Skip To Main Content
Douglas Yee on Muck Rack

Douglas Yee

As seen in: Nature, WCCO-TV (Minneapolis, MN), MDPI, JAMA Oncology, Cell Reports Medicine, Healio, MinnPost, Texas Medical Center, France Today, OncLive and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Douglas

Contact Douglas, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Tumor-specific lncRNA IGF1R-AS1 trans-regulates chromatin interactions associated with oncogenic MYC signaling

|
By Yongyong Yang, Ting-You Wang, Joshua Fry, Yingming Li, Qingshu Meng, Qingxiang Guo, Nathan Patchen, Kyle White, Abhirami Ramakrishnan, Yanan Ren, Qianru Li, Xingxing Zhang, Taufeeque Ali, Courtney Dawes, Stamatina Fragkogianni, Parker Irvin, Sk Kayum Alam, Luke H. Hoeppner, Xihong Zhang, Douglas Yee, Adam B. Weiner, Edward Schaeffer, Yang Liu Verified, Xiaoyang Zhang, Scott M. Dehm, Qi Cao, Rendong Yang
| Nature Verified
Abstract LncRNAs have emerged as pivotal regulators in the development and progression of various human cancers. However, understanding the precise mechanisms by which lncRNAs influence cancer progression remains a substantial challenge, largely due to their cell type- and tissue-specific expression patterns and the lack of well-defined functional domains or motifs.
Open in Who Shared Issue with article?

Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer

|
By Michael Campbell, Denise Wolf, Christina Yau, Lamorna Brown-Swigart, Isela R. Gallagher, Zelos Zhu, Jennifer Bolen, Scott VandenBerg, Clifford Hoyt, Hidetoshi Mori, Alexander T. Borowsky, Jane Perlmutter, Rita Nanda, Minetta C. Liu, Douglas Yee, Angela DeMichele, Nola Hylton, Lajos Pusztai, Donald A. Berry, Gillian L. Hirst, Emanuel F. Petricoin, Laura van’t Veer, Laura Esserman, Julie Wulfkuhle, Laura Sit, Smita M. Asare
| Cell Reports Medicine Verified
Results A total of 69 HER2− patients (40 HR+HER2− and 29 TN) were randomized to receive 4 cycles of pembrolizumab in combination with weekly paclitaxel followed by anthracycline chemotherapy (Pembro+T → AC). In addition, there were 181 HER2− patients (96 HR+HER2− and 85 TN) randomized to the standard neoadjuvant chemotherapy control group (T → AC). We utilized three assay platforms to characterize the tumor immune microenvironment in these patients (Figure 1).
Open in Who Shared Issue with article?

Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial - Nature Medicine

|
By Rita Nanda, Hope Rugo, Judy Boughey, Kevin Kalinsky, Christos Vaklavas, Claudine Isaacs, Alexandra Thomas, Natsuko Onishi, Lamorna Brown-Swigart, Gillian L. Hirst, W. Fraser Symmans, Paula R Pohlmann, Angela DeMichele, Douglas Yee
| Nature Verified
Abstract Sequential adaptive trial designs can help accomplish the goals of personalized medicine, optimizing outcomes and avoiding unnecessary toxicity.
Open in Who Shared View Duplicates (2) Issue with article?
See all 15 licensed articles (17 Total)